NCT00133562撤回3 期
Prospective Double Blind Randomized Clinical Trial of Alanyl-Glutamine or Glycine in Hospitalized Children With Persistent Diarrhea or Malnutrition.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 入组人数
- 108
研究概览
简要总结
This study will determine the effect of 7 days supplementation of alanyl-glutatime or glycine on the damaged intestinal barrier function on day 8 in children with persistent diarrhea or malnutrition.
详细描述
The purpose of this study is to determine the effect of 7 days supplementation of alanyl-glutamine or glycine on the damaged intestinal barrier function, measured by lactulose/mannitol test on day 8, in children with persistent diarrhea or malnutrition; on diarrhea frequency and duration, weight gain, protein loss, intestinal inflammation, and lactoferrin excretion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 3 Months 至 3 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Children ages 3 to 36 months with a history of persistent diarrhea (3 or more unformed stools/day) for >2 weeks or height-for-age Z-score (HAZ) less than negative 1, which is the median of HAZ score in children at HIAS.
- •Be an inpatient and willing to stay for 7 nights at HIAS.
- •Child´s parent or guardian must sign informed consent..
排除标准
- •Children exclusively breast-fed (Reason: The diet needs to be controlled in order to evaluate the study treatment effect)
- •Children who participated in the community study or any other study within the past two years (Reason: The children in the community study will have received glutamine.)
- •Children with suspected other illnesses as indicated by fever >102º F at time of screening off antipyretics
- •Children with suspected systemic disease at the time of screening including but not limited to shock, meningitis, sepsis, pneumonia, tuberculosis, varicella
- •Severe malnutrition defined as HAZ <-3 or WAZ <-3.5 or any child weighing <10 lbs. (4.5 kg) or any child with a weight-to-height ratio <60% of the NCHS age adjusted norm.
研究者
相似试验
终止
不适用
Glycine Supplement for Severe COVID-19COVID-19SARS-CoV InfectionSARS (Severe Acute Respiratory Syndrome)SARS PneumoniaARDS, HumanPneumonia, ViralNCT04443673Instituto Nacional de Enfermedades Respiratorias59
撤回
3 期
Clinical Trial of Alanyl-Glutamine or Glycine in Children With Persistent Diarrhea or MalnutritionDiarrhea, MalnutritionNCT00338221University of Virginia108
已完成
1 期
A Clinical Study of Alanyl-Glutamine for Reduction of Post-Myomectomy AdhesionsPelvic AdhesionsNCT01701193Temple Therapeutics BV47
终止
2 期
Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile InfectionClostridium Difficile InfectionNCT02053350University of Virginia7
招募中
2 期
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)Clostridium Difficile InfectionClostridium Difficile DiarrheaClostridia Difficile ColitisClostridioides Difficile InfectionNCT04305769University of Virginia260